NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Smart Analysis and Decision-Making for Emerging Infectious Diseases

Enrolling By InvitationNA

Sponsor: Peking University

Conditions: Emerging Infectious Diseases, COVID-19, Influenza, Mpox (Monkeypox), Dengue Fever

Interventions: Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices

Countries: China

Emerging infectious diseases, such as COVID-19, mpox, and dengue fever, are characterized by rapid transmission, wide impact, and high uncertainty, posing ongoing threats to global public health. While China achieved significant success in COVID-19 control, the response also revealed key challenges, including fragmented information, delayed risk perception, experience-dependent assessment, and inefficiencies in complex decision-making. This study aims to establish a smart technology system covering the full chain of "risk perception-situational assessment-intelligent decision-making-comprehensive evaluation." Specific objectives include: Constructing a global disease burden database and knowledge graph for emerging infectious diseases; Developing early risk assessment models covering the full transmission spectrum (cross-species, imported, and local outbreak); Building an AI-driven collective intelligence decision-support tool for epidemic control; Developing precise intervention frameworks and comprehensive evaluation indicators for key populations (e.g., elderly, students); Integrating the above technologies into a multi-agent toolkit and evaluating its effectiveness through a cluster randomized controlled trial involving at least 36 district/county-level CDC clusters across five provinces/municipalities (Guangdong, Zhejiang, Hubei, Sichuan, and Shanghai). Three eligible CDC staff members will be enrolled from each participating cluster, including one CDC director or relevant leader responsible for infectious disease prevention and control and two professional staff members engaged in acute infectious disease surveillance, risk assessment, decision-making, or emergency response. Accordingly, at least 108 participants will be enrolled, and the final anticipated enrollment will be determined by the total number of participating clusters. The intervention group will use the smart toolkit alongside routine practices, while the control group will follow routine practices only. The primary outcome is response time for epidemic assessment and decision-making (hours from risk perception to decision completion). Secondary outcomes include epidemic control effectiveness, user satisfaction, and socioeconomic benefits. The intervention period is 3 months, starting around July 2026 and ending in December 2027. This study has been approved by the Peking University Biomedical Ethics Committee. The study does not involve individual patient data; all data are aggregated at the district/county level from CDC sources or publicly available data. Anonymous questionnaires do not collect any personal identifiable information.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Working at a participating district/county-level CDC in one of the five provinces/municipalities (Zhejiang, Guangdong, Hubei, Sichuan, or Shanghai) where at least one emerging infectious disease (COVID-19, mpox, influenza, dengue, chikungunya, or avian influenza) has occurred.
* Being one of the three designated participants from the participating CDC cluster: one CDC director or relevant leader responsible for infectious disease prevention and control, or one of two professional staff members engaged in acute infectious disease surveillance, risk assessment, decision-making, risk management, or emergency response.
* Currently responsible for or involved in infectious disease epidemic prevention and control work, including information collection, risk perception, risk assessment, decision-making, risk management, and emergency response at the CDC.
* Willing to voluntarily participate in this study and provide written informed consent.

Exclusion Criteria:

* Under 18 years of age.
* Diagnosed with severe mental illness or other conditions that impede normal communication.
* Employed in the current CDC position for less than 1 year.

Locations (1)

Beijing, Beijing Municipality, China